Purple Biotech Presents Data of its Phase 1 Head & Neck Canc

Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024

Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024

streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

Israel , Rehovot , Hamerkaz , Gil Efron , Lior Fhima , Michael Schickler , University Of Chicago , Purple Biotech Ltd , Exchange Commission , Regulatory Affairs , Drug Administration , Company Contact , Bristol Myers Squibb , Objective Response Rate , Disease Control Rate , European Society , Medical Oncology Targeted Anticancer Therapies , Sari Rosenberg , Assistant Professor , Purple Biotech , Neck Cancer Scientific Advisory Board , Squamous Cell Carcinoma , Chief Executive Officer , Insulin Receptor Substrates , Signal Transducer , Tumor Associated Antigen , Looking Statements , Safe Harbor , Private Securities Litigation Reform Act , Annual Report , Registration Statements ,